Director, Immunogenicity Risk Assessment

Janssen Research & Development, L.L.C., a division of Johnson & Johnson's Family of Companies is recruiting for a Director, Immunogenicity Risk Assessment located in either Spring House, PA or Cambridge, MA.

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more at https://www.jnj.com/ .

Biologics Discovery is an integral part of the Janssen Therapeutics Discovery organization. We are committed to delivering high-quality drug candidates in partnership with all Janssen Therapeutic Area (TA) discovery organizations. We can accomplish our mission by building deep expertise in large molecule end-to-end discovery such as Antibody discovery, protein engineering and optimization, molecular attribute characterization, target protein & expression sciences, and platform biology/in vitro pharmacology/assay development. Our success also depends on close partnerships with internal and external organizations in a matrix environment.

We are currently seeking a highly motivated and experienced individual to join our organization as Director. This position will require candidates to possess deep knowledge of large molecule immunogenicity risk assessment. Using a mix of internal and external resources, this role will collaborate with key partners in the TAs and other internal groups to support portfolio advancement, implementation, and evolve strategy in immunogenicity risk assessment.

Key Responsibilities:

• Provide scientific leadership in immunogenicity risk assessment for Therapeutic Discovery.

• Lead matrixed cross-functional immunogenicity risk assessments on all protein portfolios to develop and deliver outstanding biotherapeutics for all Therapeutic Areas.

• Design and implement strategies to ensure delivering best-in-class biologics for our patients.

• Leverage clinical development experience to further refine and work toward increased confidence in immunogenicity risk mitigation during discovery phase.

• Build and maintain positive relationships with external partners, including academic collaborations and industry experts, to demonstrate external expertise and drive innovation.